[go: up one dir, main page]

MX2009010205A - Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c. - Google Patents

Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.

Info

Publication number
MX2009010205A
MX2009010205A MX2009010205A MX2009010205A MX2009010205A MX 2009010205 A MX2009010205 A MX 2009010205A MX 2009010205 A MX2009010205 A MX 2009010205A MX 2009010205 A MX2009010205 A MX 2009010205A MX 2009010205 A MX2009010205 A MX 2009010205A
Authority
MX
Mexico
Prior art keywords
hcv
nonepimerizable
protease
compounds
ketoamide inhibitors
Prior art date
Application number
MX2009010205A
Other languages
English (en)
Inventor
Neng-Yang Shih
Srikanth Venkatraman
F George Njoroge
Vincent S Madison
Francisco Velazquez
Wanli Wu
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009010205A publication Critical patent/MX2009010205A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención describe compuestos novedosos, que tienen actividad inhibidora de proteasa de HCV así como métodos para preparar dichos compuestos; en otra modalidad, la invención describe composiciones farmacéuticas que comprenden los compuestos así como métodos para usarlos para tratar trastornos asociados con la proteasa de HCV.
MX2009010205A 2007-03-23 2008-03-20 Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c. MX2009010205A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91973107P 2007-03-23 2007-03-23
PCT/US2008/003652 WO2009008913A2 (en) 2007-03-23 2008-03-20 P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease

Publications (1)

Publication Number Publication Date
MX2009010205A true MX2009010205A (es) 2009-10-19

Family

ID=40091588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010205A MX2009010205A (es) 2007-03-23 2008-03-20 Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.

Country Status (7)

Country Link
US (1) US20100074867A1 (es)
EP (1) EP2139854A2 (es)
JP (1) JP2010522172A (es)
CN (1) CN101679240A (es)
CA (1) CA2681624A1 (es)
MX (1) MX2009010205A (es)
WO (1) WO2009008913A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
MX2009011867A (es) * 2007-05-03 2010-03-22 Array Biopharma Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
BRPI0811447A2 (pt) * 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
BRPI0911260A2 (pt) * 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010122682A1 (ja) 2009-04-24 2010-10-28 株式会社カネカ Ｎ－アルコキシカルボニル－ｔｅｒｔ－ロイシンの製造法
CN105001302A (zh) * 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
AU2011266626B2 (en) * 2010-06-16 2014-10-23 Medivir Uk Limited New cathepsin S protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions
CN109563033B (zh) * 2016-06-21 2023-04-04 奥瑞恩眼科有限责任公司 脂族脯氨酰胺衍生物
EA201990069A1 (ru) * 2016-06-21 2019-06-28 ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи Производные гетероциклического пролинамида
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AU2001276988B2 (en) * 2000-07-21 2007-01-25 Dendreon Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
ATE514691T1 (de) * 2004-02-27 2011-07-15 Schering Corp Neue ketoamide mit cyclischen p4 als inhibitoren der ns3-serinprotease von hepatitis-c-virus

Also Published As

Publication number Publication date
US20100074867A1 (en) 2010-03-25
WO2009008913A3 (en) 2009-03-19
CA2681624A1 (en) 2009-01-15
WO2009008913A2 (en) 2009-01-15
EP2139854A2 (en) 2010-01-06
JP2010522172A (ja) 2010-07-01
CN101679240A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
MX2009011064A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
TW200602037A (en) Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
TW200938526A (en) Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2005087725A3 (en) Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
MY140710A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
ECSP066626A (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
ECSP066792A (es) Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
WO2010021717A3 (en) Hcv protease inhibitors
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
MX2008001538A (es) Aril piridinas y metodos para su uso.
MX2011011272A (es) Procesos e intermediarios.
MX2009003763A (es) Inhibidores de metaloproteasa derivados de heterociclicos.
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
NO20075370L (no) Alfa-ketoamidforbindelser som cysteinproteaseinhibitorer
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen